Vistagen Therapeutics Investors Invited to Join Securities Fraud Lawsuit Led by Schall Law Firm

Investors Encouraged to Join Vistagen Therapeutics Class Action Lawsuit

In a significant development for shareholders, the Schall Law Firm, a prominent national firm specializing in shareholder rights litigation, has announced a class action lawsuit against Vistagen Therapeutics, Inc. (NASDAQ: VTGN). This lawsuit arises from the company's alleged violations of the Securities Exchange Act of 1934, particularly sections 10(b) and 20(a), including Rule 10b-5.

Background of the Case

The class action focuses on investors who purchased Vistagen's securities between April 1, 2024, and December 16, 2025— a period which the firm has termed the "Class Period." During this time, Vistagen is accused of making false and misleading claims regarding the success of its drug candidate, fasedienol, specifically in relation to the PALISADE-2 trial results. The firm has asserted that Vistagen misled investors by presenting these results as positive, while underplaying the associated risks of clinical failure. As a result, many investors suffered significant financial losses when the truth was eventually disclosed.

Legal Representation and Next Steps

Shareholders who believe they have incurred losses during this class period are urged to reach out to the Schall Law Firm for more information. Individuals who wish to join the lawsuit must do so before the cutoff date of March 16, 2026. Contact can be made directly to Brian Schall at the firm or through their website. Current non-participating shareholders will remain in the class as absent members unless they opt to join actively.

Participating in this lawsuit not only offers a chance for recovery of losses but also serves as a statement against corporate misconduct. The Schall Law Firm’s dedication to investor rights has positioned them successfully in similar securities litigation, and they are ready to represent Vistagen's shareholders vigorously.

Implications for Investors

Investors should be aware that until the class is certified, they may not be represented by an attorney, highlighting the importance of taking action sooner rather than later. By joining the lawsuit, investors can lend their voices to hold Vistagen accountable for its actions.

Schall Law Firm has emphasized their commitment to advocating for shareholders globally and has vast experience in representing interests involving securities class actions. The firm invites any investors who have questions about their rights or shareholding status to contact them free of charge.

Conclusion

As Vistagen Therapeutics navigates these legal challenges, the ongoing support and participation of its investors will be crucial. Those affected should act swiftly to ensure their voices are heard and to seek redress for possible financial damages. Be a part of the movement to uphold transparency and integrity within financial markets through active engagement in this lawsuit.

For more detailed information, investors are encouraged to reach out via the provided contact details. The impact of this case may ripple through Vistagen’s corporate future, making every shareholder's involvement vital.